BPC-157 — analytical characterisation

§6Analytical characterisation

§6.1Chromatographic conditions

Column

C18, 4.6 × 250 mm, 5 µm; a polar-embedded or aqueous-compatible C18 phase improves retention of this hydrophilic sequence

Mobile phase and gradient

A: 0.1 % trifluoroacetic acid in water; B: acetonitrile. Gradient 5–35 % B over 25 min — a shallow low-organic gradient is required because the peptide is highly polar and elutes near the void on a conventional method

Detection

UV 214 nm only. The sequence contains no aromatic residue, so 280 nm detection is impossible. A certificate reporting a 280 nm purity for BPC-157 is prima facie erroneous, and the Institute has recorded this specific error in submitted third-party data

Retention

Early; poor retention is the principal method-development challenge and a common cause of apparent purity overestimation when impurities coelute with the void

§6.2Identity by mass spectrometry

[M+H]⁺ at m/z 1420.5; [M+2H]²⁺ at m/z 710.8. Average mass 1419.5 ± 1 Da.^[3]

§6.3Related substances and degradation

Table 7. Related substances recorded for BPC-157, with the process or storage route that generates each and its analytical signature.

Degradation routes

• Aspartimide formation at the Asp-Asp motif is the dominant synthesis and storage route
• No oxidation-sensitive residues, so the compound is unusually oxidatively stable
• Hydrolysis of the C-terminal free acid is not applicable; the C-terminus is already the acid
• The triproline motif resists enzymatic degradation, which is the basis of the stability claims for this peptide

§7Presentation, reconstitution and storage

§7.1Presentation and reconstitution

Presentation

Lyophilised powder in vial (research supply only); some suppliers offer oral capsule presentations

Reconstitution

A 5 mg vial with 2.5 mL gives 2 mg/mL; a 250 µg quantity is then 0.125 mL, that is 12.5 units on a U-100 syringe.

Storage, lyophilised

−20 °C, desiccated. The absence of oxidation-sensitive residues makes this peptide comparatively forgiving of imperfect storage

Storage, reconstituted

2–8 °C. No published stability-indicating study supports any specific in-use period, though the sequence chemistry suggests it is among the more stable peptides in aqueous solution

In-use period

No supported claim

BPC-157 illustrates a distinction the Institute considers important: analytical quality and evidential support are independent. Material can be, and often is, chemically excellent while the clinical evidence base remains effectively empty.

§7.2In-use stability

Applicable standards: CEI-MS-01 · CEI-MS-02 · CEI-MS-03 · CEI-MS-04 · CEI-MS-05 · CEI-MS-06. The full series is at methodological standards.

Working calculators: reconstitution and insulin-unit conversion · purity against peptide content · certificate minimum-data checker.

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

1. United States Pharmacopeial Convention. General Chapter ⟨1225⟩ Validation of Compendial Procedures. United States Pharmacopeia — National Formulary (USP–NF) 2024;USP 2024 Issue 1. identifier not held by the Institute
2. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Q2(R2) Validation of Analytical Procedures. ICH Harmonised Guideline 2023;Step 4 version, 1 November 2023. identifier not held by the Institute
3. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Q6B Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products. ICH Harmonised Tripartite Guideline 1999;Step 4 version. identifier not held by the Institute
4. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Q1A(R2) Stability Testing of New Drug Substances and Products. ICH Harmonised Tripartite Guideline 2003;Step 4 version. identifier not held by the Institute
5. Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharmaceutical Research 2010;27(4):544–575. doi:10.1007/s11095-009-0045-6 · PMID 20143256

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.